VENUSREM.NS Stock Analysis
VE
Neutral
Based on Eyestock quantitative analysis, VENUSREM.NS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Venus Remedies Ltd. engages in the manufacture and trade of pharmaceutical products. The company is headquartered in Panchkula, Haryana and currently employs 998 full-time employees. The firm is a global injectable manufacturer, possessing a wide product basket catering to therapeutic segments of anti-infective specially in antimicrobial resistance (AMR), oncology, skin and wound care and pain management. The firm operates in the Pharmaceutical Formulation segment. The company manufactures products catering to the critical care and super specialty segments. The firm's product portfolio includes formulations such as injectables, tablets, and topical preparations. The firm offers solutions in the domains of antimicrobial resistance (AMR), oncology, skin & wound care, neurology, anticoagulants, pain management, herbal portfolio and disinfectants. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful and Nervolize. The company has three manufacturing facilities.